Compare GOCO & AEON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GOCO | AEON |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.5M | 26.8M |
| IPO Year | 2020 | N/A |
| Metric | GOCO | AEON |
|---|---|---|
| Price | $1.33 | $0.98 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $4.75 | ★ $7.20 |
| AVG Volume (30 Days) | ★ 103.9K | 67.0K |
| Earning Date | 03-31-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $361,845,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.31 | $0.38 |
| 52 Week High | $11.88 | $1.45 |
| Indicator | GOCO | AEON |
|---|---|---|
| Relative Strength Index (RSI) | 38.32 | 42.69 |
| Support Level | N/A | $0.94 |
| Resistance Level | $2.48 | $1.12 |
| Average True Range (ATR) | 0.21 | 0.13 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 2.88 | 9.65 |
GoHealth Inc is a health insurance marketplace and Medicare-focused digital health company whose purpose is to compassionately ensure consumers' peace of mind when making healthcare decisions so consumers can focus on living life. It offers Medicare plans, including, but not limited to, Medicare Advantage, Medicare Supplement and prescription drug plans. Its proprietary technology platform leverages modern machine-learning algorithms, powered by over two decades of insurance purchasing behavior, to reimagine the process of matching a health plan to a consumer's specific needs.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.